

Nikolai A Podoltsev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4147182/publications.pdf>

Version: 2024-02-01

121
papers

3,364
citations

236925

25
h-index

161849

54
g-index

121
all docs

121
docs citations

121
times ranked

4106
citing authors

#	ARTICLE	IF	CITATIONS
1	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	27.0	796
2	Mutation of <i>NLR4</i> causes a syndrome of enterocolitis and autoinflammation. <i>Nature Genetics</i> , 2014, 46, 1135-1139.	21.4	417
3	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1317-1326.	10.7	148
4	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1193-1207.	4.9	119
5	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	5.2	114
6	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	5.2	100
7	Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2017, 130, 722-722.	1.4	84
8	Selecting initial treatment of acute myeloid leukaemia in older adults. <i>Blood Reviews</i> , 2017, 31, 43-62.	5.7	74
9	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e317-e327.	4.6	71
10	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. <i>Blood Advances</i> , 2020, 4, 2192-2201.	5.2	68
11	Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. <i>Blood Reviews</i> , 2021, 47, 100773.	5.7	63
12	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. <i>Journal of Clinical Oncology</i> , 2017, 35, 3417-3424.	1.6	61
13	A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. <i>Nature Communications</i> , 2019, 10, 366.	12.8	60
14	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840.	2.5	59
15	Follow-up of patients with R/R <i>FLT3</i> -positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
16	Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. <i>Blood</i> , 2020, 135, 1696-1703.	1.4	54
17	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
18	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Reviews</i> , 2020, 42, 100706.	5.7	54

#	ARTICLE	IF	CITATIONS
19	Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821.	1.4	45
20	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 564-564.	1.4	41
21	Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 2245-2253.	5.2	36
22	The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. <i>Blood Reviews</i> , 2016, 30, 1-10.	5.7	32
23	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. <i>Blood Advances</i> , 2020, 4, 1615-1623.	5.2	32
24	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
25	Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. <i>Leukemia</i> , 2021, 35, 1643-1660.	7.2	29
26	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. <i>Cancer</i> , 2019, 125, 4241-4251.	4.1	28
27	Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. <i>Blood Cancer Journal</i> , 2018, 8, 55.	6.2	26
28	Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2180-2190.	1.3	24
29	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.	1.4	23
30	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	23
31	Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 997.e1-997.e11.	1.2	20
32	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 397-408.	1.3	19
33	A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results. <i>Blood</i> , 2020, 136, 16-17.	1.4	19
34	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. <i>Cancer</i> , 2017, 123, 3754-3762.	4.1	18
35	Trends and factors affecting the US adult hematology workforce: a mixed methods study. <i>Blood Advances</i> , 2019, 3, 3550-3561.	5.2	18
36	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	5.2	18

#	ARTICLE	IF	CITATIONS
37	Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. <i>Blood</i> , 2018, 131, 1486-1489.	1.4	17
38	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	1.3	17
39	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
40	Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 303-307.	2.3	15
41	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187.	1.3	15
42	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
43	Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 177-189.	2.2	14
44	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 766-770.e4.	0.4	13
45	The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. <i>Blood Advances</i> , 2018, 2, 2681-2690.	5.2	13
46	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 92-99.	1.6	13
47	Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e712-e723.	0.4	12
48	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
49	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11
50	Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. <i>Cancer</i> , 2019, 125, 4084-4095.	4.1	10
51	Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. <i>Cancer</i> , 2018, 124, 4211-4220.	4.1	9
52	RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 3181-3187.	1.3	9
53	Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. <i>International Journal of Cancer</i> , 2020, 147, 948-957.	5.1	9
54	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 873.e1-873.e13.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747.	2.5	9
56	European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. <i>HemaSphere</i> , 2022, 6, e721.	2.7	9
57	Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. <i>Oxford Medical Case Reports</i> , 2014, 2014, 138-140.	0.4	7
58	A rare case of visceral leishmaniasis in an immunocompetent traveler returning to the United States from Europe. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006727.	3.0	7
59	Emerging agents and regimens for polycythemia vera and essential thrombocythemia. <i>Biomarker Research</i> , 2021, 9, 40.	6.8	7
60	Chemoimmunotherapy and Withdrawal of Immunosuppression for Monomorphic Posttransplant Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 716-720.	0.4	6
61	A Patient With Pancytopenia, Intractable Epistaxis, and Metastatic Prostate Cancer: How Correct Diagnosis of Primary Hyperfibrinolysis Helps to Stop the Bleeding. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e545-e548.	1.9	6
62	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
63	Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. <i>Annals of Hematology</i> , 2018, 97, 2333-2343.	1.8	6
64	What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1169-1173.	1.8	6
65	Laboratory evaluation and prognostication among adults and children with <i>CEBPA</i> mutant acute myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 86-95.	1.3	6
66	Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. <i>Blood</i> , 2020, 136, 22-23.	1.4	6
67	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 211-219.	4.9	6
68	A case of acute myeloid leukemia with unusual germline <i>CEBPA</i> mutation: lessons learned about mutation detection, location, and penetrance. <i>Leukemia and Lymphoma</i> , 2021, 62, 1251-1254.	1.3	6
69	Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 646-651.	0.9	5
70	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1195-1202.	1.3	5
71	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	1.4	5
72	Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. <i>Blood Advances</i> , 2022, 6, 376-385.	5.2	5

#	ARTICLE	IF	CITATIONS
73	Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152. <i>Blood</i> , 2021, 138, 3407-3407.	1.4	5
74	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. <i>Blood Advances</i> , 2022, 6, 3339-3342.	5.2	5
75	Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018, 132, 231-231.	1.4	4
76	First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2014, 124, 529-529.	1.4	4
77	Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. <i>Annals of Hematology</i> , 2022, 101, 1145-1147.	1.8	4
78	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. <i>Blood</i> , 2015, 126, 1138-1138.	1.4	4
79	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	1.4	4
80	Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1766-1770.	1.4	4
81	Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. <i>Leukemia</i> , 0, , .	7.2	4
82	Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. <i>Leukemia Research</i> , 2020, 90, 106315.	0.8	3
83	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule 1 (CLL1) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E175-E179.	4.1	3
84	Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e551-e558.	0.4	3
85	Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. <i>Leukemia Research</i> , 2021, 109, 106629.	0.8	3
86	Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. <i>Current Opinion in Hematology</i> , 2021, 28, 110-121.	2.5	3
87	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab. <i>Blood</i> , 2019, 134, 3809-3809.	1.4	3
88	Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. <i>Blood</i> , 2019, 134, 2957-2957.	1.4	3
89	Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic Institution. <i>Blood</i> , 2016, 128, 3538-3538.	1.4	3
90	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110434.	2.5	3

#	ARTICLE	IF	CITATIONS
91	European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. <i>Blood</i> , 2021, 138, 240-240.	1.4	3
92	Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1895-1898.	1.8	2
93	Acute myeloid leukemia presenting as bilateral adrenal hemorrhage. <i>Annals of Hematology</i> , 2019, 98, 2421-2423.	1.8	2
94	Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2020, 13, 447-460.	2.2	2
95	Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101-S102.	2.0	2
96	Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database. <i>Blood</i> , 2019, 134, 2949-2949.	1.4	2
97	Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 29-29.	1.4	2
98	Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. <i>Blood</i> , 2018, 132, 3580-3580.	1.4	2
99	Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2343-2350.	2.5	1
100	Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. <i>International Journal of Cancer</i> , 2020, 146, 3523-3523.	5.1	1
101	Isolated trisomy 11 in patients with acute myeloid leukemia “ is the prognosis not as grim as previously thought?*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2254-2257.	1.3	1
102	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e483-e487.	0.4	1
103	Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). <i>Blood</i> , 2019, 134, 4748-4748.	1.4	1
104	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2015, 126, 3285-3285.	1.4	1
105	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	1.4	1
106	Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. <i>Blood</i> , 2021, 138, 2583-2583.	1.4	1
107	Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based Study. <i>Blood</i> , 2020, 136, 21-22.	1.4	1
108	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-10.	1.3	0
110	Post-Transplantation Lymphoproliferative Disorders (PTLD) Management in Solid Organ Transplantation (SOT) Recipients. <i>Blood</i> , 2011, 118, 4941-4941.	1.4	0
111	Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study. <i>Blood</i> , 2012, 120, 4944-4944.	1.4	0
112	Efficient Engraftment and Disease Replication of Myelodysplastic Syndromes Using a Novel Humanized Mice Model. <i>Blood</i> , 2015, 126, 4100-4100.	1.4	0
113	Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Blood</i> , 2015, 126, 4455-4455.	1.4	0
114	Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. <i>Blood</i> , 2016, 128, 394-394.	1.4	0
115	Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. <i>Blood</i> , 2017, 130, 675-675.	1.4	0
116	Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. <i>Blood</i> , 2018, 132, 3538-3538.	1.4	0
117	Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. <i>Blood</i> , 2021, 138, 4092-4092.	1.4	0
118	Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. <i>Blood</i> , 2021, 138, 182-182.	1.4	0
119	Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. <i>European Journal of Rheumatology</i> , 2023, 9, 215-216.	0.6	0
120	Myocardial infarction in a young adult undergoing induction treatment for acute lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 675-7.	0.3	0
121	Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. <i>Leukemia Research</i> , 2022, 119, 106903.	0.8	0